TRUE™ Patch

TRUE™ Patch

Tissue patches are routinely used in surgery for soft tissue repair and reconstruction throughout the body in cardiovascular, orthopedic, abdominal and thoracic wall applications.

Current therapies are predominantly xenogeneic, allogeneic or synthetic biomaterials such as bovine pericardium, ePTFE, small intestinal submucosa, and dermal grafts. However, issues persist: incomplete tissue remodeling, mechanical mismatch, and reduced vascularity.

TRUE™ Patch has been developed to overcome these limitations and deliver a 100% biological soft tissue replacement that is:

  • Acellular and non-immunogenic human cell-derived matrix
  • Regenerative through robust host cell recruitment
  • Suitable for a range of applications through highly tunable mechanical properties, sizes and shapes

TRUE™ Patch is suitable for a wide range of clinical applications:

  • Vascular
  • Cardiac
  • Dura
  • Skin
  • Bladder

TRUE™ Patch vs. Pericardium

Pericardial tissue is often used as a patch in cardiovascular surgeries to close intracardiac and septal defects, for vascular reconstruction and repairs, and in other applications such as hernia repair and dura mater substitution. Bovine pericardium is typically cross-linked in glutaraldehyde and elimination of residual glutaraldehyde is important in calcification prevention post implantation (Li et al., Ann Vasc Surg, 2011).

Side by side testing of porcine pericardial tissue and TRUE Patch tissue demonstrates no mechanical compromise while delivering superior long term solution (Syedain et al, Heart Valve Society Presentation 2019).

There is finally a TRUE™ Tissue alternative that can be available off-the-shelf and meet the challenging in vivo implantation requirements. Contact us to discuss how TRUE™ Patch can be used in your medical device development.

News

Vascudyne Image

Vascudyne Receives BioBusiness Award from Regenerative Medicine Minnesota for Treatment of Nerve Injury

VASA Conference Image

Vascudyne Announces Presentation of First Clinical Results of TRUE AVC™ in Hemodialysis Access at the VASA Conference

Vascudyne Lab

Regenerative Medicine Company Vascudyne Relocates to High Capacity GMP Manufacturing Facility

Autm better world project image

Vascudyne’s TRUE Tissue Technology is a Top 3 2022 Better World Project Award Finalist

Regenerative Medicine Vascular Graft for Hemodialysis Access

Regenerative Medicine Company Vascudyne Closes $10 Million Series A Financing

Vascudyne announces successful First Human Use of TRUE™ Vascular Graft for hemodialysis access

Vascudyne’s CSO presents at the Heart Valve Society Meeting on tissue remodeling of engineered valved conduit evaluated at 52 weeks in the growing lamb

Lab-created heart valves can grow with the recipient article published in Science Translational Medicine

Proud Member of:

6 + 2 =

Copyright 2021 | Vascudyne, Inc.

Privacy Policy